Abstract:The effects of vitamin D on osteoblast mineralization are well documented. Reports of the effects of vitamin D on osteoclasts, however, are conflicting, showing both inhibition and stimulation. Finding that resorbing osteoclasts in human bone express vitamin D receptor (VDR), we examined their response to different concentrations of 25-hydroxy vitamin D3 [25(OH)D3] (100 or 500 nmol·L−1) and 1,25-dihydroxy vitamin D3 [1,25(OH)2D3] (0.1 or 0.5 nmol·L−1) metabolites in cell cultures. Specifically, CD14+ monocytes were cultured in charcoal-stripped serum in the presence of receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Tartrate-resistant acid phosphatase (TRAP) histochemical staining assays and dentine resorption analysis were used to identify the size and number of osteoclast cells, number of nuclei per cell and resorption activity. The expression of VDR was detected in human bone tissue (ex vivo) by immunohistochemistry and in vitro cell cultures by western blotting. Quantitative reverse transcription-PCR (qRT-PCR) was used to determine the level of expression of vitamin D-related genes in response to vitamin D metabolites. VDR-related genes during osteoclastogenesis, shown by qRT-PCR, was stimulated in response to 500 nmol·L−1 of 25(OH)D3 and 0.1–0.5 nmol·L−1 of 1,25(OH)2D3, upregulating cytochrome P450 family 27 subfamily B member 1 (CYP27B1) and cytochrome P450 family 24 subfamily A member 1 (CYP24A1). Osteoclast fusion transcripts transmembrane 7 subfamily member 4 (tm7sf4) and nuclear factor of activated T-cell cytoplasmic 1 (nfatc1) where downregulated in response to vitamin D metabolites. Osteoclast number and resorption activity were also increased. Both 25(OH)D3 and 1,25(OH)2D3 reduced osteoclast size and number when co-treated with RANKL and M-CSF. The evidence for VDR expression in resorbing osteoclasts in vivo and low-dose effects of 1,25(OH)2D3 on osteoclasts in vitro may therefore provide insight into the effects of clinical vitamin D treatments, further providing a counterpoint to the high-dose effects reported from in vitro experiments.

1 Alpha,25-Dihydroxyvitamin D-3 Inhibits The Differentiation And Bone Resorption By Osteoclasts Generated From Wistar Rat Bone Marrow-Derived Macrophages

1α,25-Dihydroxyvitamin D3 inhibits the differentiation and bone resorption by osteoclasts generated from Wistar rat bone marrow-derived macrophages.

[1,25 (OH), Dihydroxyvitamin D3 Induces the Formation of Osteoclasts from Mononuclear Cells of Rat Marrow].

Effect of 1,25(OH)2D3 on the Expression of RANKL and Osteoprotegerin Mrna in Primary Rat Osteoblasts

Effects of 1a,25-Dihydroxyvitamin D3-26,23-Lactone and Its Intermediate Metabolites on Bone Metabolism in vivo and in vitro

1alpha,25-dihydroxyvitamin D3 regulates the expression of membrane-type matrix metalloproteinase-1 in normal human osteoblast-like cells.

Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption

1α,25‐Dihydroxyvitamin D<sub>3</sub>Regulates the Expression of Membrane‐Type Matrix Metalloproteinase‐1 in Normal Human Osteoblast‐like Cells

[Effect of the Bone Resorption Supernatant from RAW264.7 Osteoclast on the Osteogenic Activity of Mouse MC3T3-E1 Cell].

[The Effects of 1Alpha,25-Dihydroxyvitamin D3 in Regulation Matrix Metalloproteinase and Tissue Metalloproteinase Inhibitors in Human Osteoblasts].

1α,25‐Dihydroxyvitamin D3 Regulates the Expression of Membrane‐Type Matrix Metalloproteinase‐1 in Normal Human Osteoblast‐like Cells

Vitamin D Inhibition of TRPV5 Expression During Osteoclast Differentiation

2α-Substituted Vitamin D Derivatives Effectively Enhance the Osteoblast Differentiation of Dedifferentiated Fat Cells

1-Α,25-dihydroxyvitamin D3 Potentiates Avian Osteoclast Activation by Increasing the Formation of Zipper-Like Structure Via Src/Rac1 Signaling.

Histochemical examination of the effects of high-dose 1,25(OH)2D3 on bone remodeling in young growing rats

Histochemical examination of the effects of high-dose 1,25(OH) 2 D 3 on bone remodeling in young growing rats

1-Alpha,25-dihydroxyvitamin D-3 Potentiates Avian Osteoclast Activation by Increasing the Formation of Zipper-Like Structure Via Src/Rac1 Signaling

Adrenocorticotropic Hormone and 1,25-Dihydroxyvitamin D3 Enhance Human Osteogenesis in Vitro by Synergistically Accelerating the Expression of Bone-Specific Genes.

1Α,25-Dihydroxyvitamin D3 Induces the Expression of Membrane-type Matrix Metalloproteinase-1 in Normal Human Osteoblast-like Cells

[Effects of 1 Alpha(oh)d3 on Trabecular and Cortical Bone in Ovariectomized Rats].

Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts